Real world, open label experience with lacosamide against acute painful oxaliplatin‐induced peripheral neurotoxicity

We report the outcome of a pilot, open‐label study that tested the potential of lacosamide (200 mg/bi.d) as an effective and safe symptomatic treatment against acute painful oxaliplatin‐induced peripheral neurotoxicity (OXAIPN). Lacosamide was introduced in 18 colorectal cancer patients with evidenc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the peripheral nervous system 2020-06, Vol.25 (2), p.178-183
Main Authors: Argyriou, Andreas A., Kalofonou, Foteini, Litsardopoulos, Pantelis, Anastopoulou, Garifallia G., Psimaras, Dimitri, Bruna, Jordi, Kalofonos, Haralabos P.
Format: Article
Language:English
Subjects:
acute symptomatic neuropathy
Chemotherapy
Colorectal cancer
Colorectal carcinoma
lacosamide
neuropathic pain
Neurotoxicity
Oxaliplatin
oxaliplatin‐induced peripheral neurotoxicity
Pain
painful neuropathy
Patients
Peripheral neuropathy
Quality of life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the outcome of a pilot, open‐label study that tested the potential of lacosamide (200 mg/bi.d) as an effective and safe symptomatic treatment against acute painful oxaliplatin‐induced peripheral neurotoxicity (OXAIPN). Lacosamide was introduced in 18 colorectal cancer patients with evidence of clinically significant acute, painful OXAIPN after infusion of the third course (T1) of oxaliplatin‐based chemotherapy (FOLFOX4) and was maintained until completion of all 12 courses (T4). The OXA‐Neuropathy Questionnaire (OXA‐NQ) was used to record the severity of acute OXAIPN; the PI‐NRS estimated the severity of neuropathic pain, while the chronic OXAIPN was graded with TNSc. The EuroQOL (EQ‐5D) instrument was also applied. The Patient Global Impression of Change (PGIC) scale measured the lacosamide‐attributed perception of change. LCM‐responders were considered those with ≥50% reduction in PI‐NRS and OXA‐NQ scores at T4, compared to T1. Patients experienced on T1 a median number of acute OXAIPN symptoms of 4 and had a median neuropathic pain severity score of 6, which was strongly related to lower quality of life, according to EQ‐VAS (P 
ISSN:1085-9489
1529-8027
DOI:10.1111/jns.12374